CD44 and glioma: Thecompounds were then evaluated against glioma-initiating cells by monitoringthe level of CD44+; all the compounds decreased the level of CD44+.The results were further confirmed by in vivo experimentsin the brains of NOD-SCID mice, where compounds decreased the numberof glioma-initiating cells (Figure 53).